Nuclear Medicine Market Size, Growth, Share & Trends Analysis
Report Code
PH 3590
Published in
Jan, 2026, By MarketsandMarkets™
Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region -Global Forecast to 2030
USD 21.01 BN
MARKET SIZE, 2030
CAGR 15.1%
(2025-2030)
342
REPORT PAGES
450
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global nuclear medicine market, valued at USD 9.03 billion in 2024, stood at USD 10.41 billion in 2025 and is projected to advance at a resilient CAGR of 15.1% from 2025 to 2030, culminating in a forecasted valuation of USD 21.01 billion by the end of the period. The growth of the market is driven by the rising prevalence of cancer and cardiovascular diseases, which is accelerating the demand for diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes. Moreover, the recognition of nuclear medicine solutions is increasing at a pace worldwide due to increased investments in radioisotope production plants, nuclear pharmacies, and positive reimbursement policies in the developed countries. This is also driving the growth of the market.
KEY TAKEAWAYS
-
By RegionThe North America nuclear medicine market accounted for a 46.4% revenue share in the global nuclear medicine market 2024.
-
By TypeThe therapeutic nuclear medicine segment is projected to register a higher growth of 20.2% than the diagnostic nuclear medicine during the forecast period.
-
By ApplicationThe diagnostic applications segment accounted for a larger share of 63.9% than the therapeutic applications segment in 2024.
-
By Volume AssessmentThe diagnostic procedures segment is estimated to dominate the market in 2025.
-
By End UserThe hospitals segment accounted for the largest share in 2024.
-
Competitive LandscapeGE HealthCare, Cardinal Health, and Bayer AG are key leaders in the global nuclear medicine market, recognized for their extensive product portfolios, robust data integration capabilities, and strong presence across healthcare ecosystems.
The nuclear medicine market is growing due to the increased investments in advanced imaging technologies, effects of radiopharmaceutical products, and increased focus on regulatory compliance and clinical accuracy in the US and EU. PET/CT, SPECT/CT and automated radio pharmacy systems continue to advance and are becoming more precise and more efficient in operation, which is also spurring growth in the market. Additionally, collaboration between pharmaceutical firms, imaging suppliers, and healthcare providers to enable completely more integrated and scalable nuclear medicine solutions can prove lucrative to the growth of the market in the coming years.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Consumer trends in the nuclear medicine market are driven by changing regulatory standards, the growing complexity of the radiopharmaceutical management, and the rising use of the advanced diagnostic and therapeutic methodology. Imaging hospitals, imaging centers, and radiopharmaceutical manufacturers are the key end users driving the demand for hybrid imaging, theranostic, and automated radio pharmacy solutions. These shifts have direct implications on clinical productivity, safety, and the management of cost, which impact purchase choices and competitiveness of nuclear medicine technology providers.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing incidence and prevalence of target conditions
-
Development of alpha-radioimmunotherapy-based targeted cancer treatments
RESTRAINTS
Impact
Level
Level
-
Short half-life of radiopharmaceuticals
OPPORTUNITIES
Impact
Level
Level
-
Use of radiopharmaceuticals in neurological applications
-
Growth opportunities in emerging economies
CHALLENGES
Impact
Level
Level
-
Hospital budget cuts and high equipment costs
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing incidence and prevalence of target conditions
The growing incidence and prevalence of targeted diseases like cancer, cardiovascular diseases, and neurological diseases is a significant driving factor for the nuclear medicine market. Since these diseases can be effectively diagnosed and treated early and through specific treatment methods, the demand for nuclear imaging modalities, such as PET and SPECT, is increasing. In oncology, nuclear medicine also plays a critical role in the staging of diseases, therapy selection, and treatment monitoring. Such increasing clinical dependence on nuclear medicine processes is directly contributing to increased use of imaging systems and radiopharmaceuticals, thus propelling overall growth in the market.
Restraint: Short half-life of radiopharmaceuticals
Radiopharmaceuticals have a short half-life, which acts as a restraining factor to the nuclear medicine market. It creates challenges in production, storage, and distribution. Numerous radioisotopes have a short shelf life where they need to be near to cyclotrons or nuclear reactors and have very complex logistics. The restriction adds complexity and cost to operations of healthcare providers and restricts access to nuclear medicine procedures in remote or underserved areas. This means that the scalability of the adoption and spread of nuclear medicine services is limited.
Opportunity: Use of radiopharmaceuticals in neurological applications
The nuclear medicine market has great potential in the growing application of radiopharmaceuticals for neurology. Nuclear imaging modalities like PET and SPECT are gradually used in the diagnosis and early management of neurological diseases, including Alzheimer's, Parkinson's, and epilepsy. Advanced neuro-specific radiotracers are enhancing the potential of identifying functional and molecular alterations in the brain at the initial stages of the disease. This increasing clinical adoption will stimulate the demand for specialized radiopharmaceuticals and complex imaging systems, which would promote market growth.
Challenge: Hospital budget cuts and high equipment costs
The high cost of nuclear medicine equipment and budget cuts in hospitals is a major challenge to the growth of the nuclear medicine market. Complex imaging systems like the PET/CT and the SPECT/CT involve huge capital investment, as well as maintenance and compliance costs. Financial issues in hospitals can postpone the updating of equipment and prevent the introduction of new technologies in nuclear medicine. The issue is especially pronounced in mini-health centers and developing markets where limited budgets restrict access to the advanced nuclear medicine services.
NUCLEAR MEDICINE MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Production and supply of PET and SPECT radioisotopes and radiopharmaceuticals used in oncology, cardiology, and neurology diagnostics | Reliable access to critical isotopes | High imaging accuracy | Improved diagnostic confidence |
 |
Nuclear pharmacy services and distribution of short-half-life radiopharmaceuticals to hospitals and imaging centers | Timely delivery of radiotracers | Reduced operational complexity | Consistent imaging workflows |
 |
Manufacturing of diagnostic and therapeutic radiopharmaceuticals, including SPECT and PET radioisotopes for cancer and neurological imaging | Stable isotope supply | High product quality | Expanded availability of nuclear medicine procedures |
 |
Development of therapeutic radiopharmaceuticals and targeted radioisotope-based treatments, particularly in oncology | Precise tumor targeting | Improved treatment outcomes | Reduced impact on healthy tissue |
 |
Production of diagnostic radiopharmaceuticals and radioisotope imaging agents for cardiac and PET imaging applications | Accurate disease detection | Quick diagnosis | Improved clinical decision-making |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
Major players in the nuclear medicine market include manufacturers of radiopharmaceuticals and radio pharmacy services used in diagnostic and therapeutic applications. Some of these manufacturers are GE HealthCare (US), Cardinal Health (US), Curium (France), and Bayer AG (Germany). These companies focus on advancing PET/CT and SPECT/CT technologies, theranostic, and ensuring a reliable supply of radioisotopes to improve clinical outcomes and regulatory compliance. The ecosystem is further strengthened by emerging startups and distributors expanding isotope production and radio pharmacy capabilities, supported by oversight from global and national regulatory authorities to ensure safety, quality, and compliance. End users include hospitals and imaging centers that deploy these solutions through ongoing collaborations.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Nuclear Medicine Market, By Type
By type, the diagnostic nuclear medicine segment led the nuclear medicine market in 2024. This is because of the high volume of the PET and SPECT imaging services that are used in the early and precise detection of cancer, cardiovascular, and neurological diseases. The segment's dominance is also favored by widespread availability of standard diagnostic radiotracers and high use in hospitals and imaging centers. This dominant role of diagnostic nuclear medicine is further being reinforced by the constant development of new hybrid imaging technologies.
Nuclear Medicine Market, By Application
By application, the diagnostic applications segment led the nuclear medicine market in 2024. This is due to the prevalence of nuclear imaging methodology in the early detection of diseases, proper diagnosis, and the planning of treatments. Both PET and SPECT scans are widely used in the fields of oncology, cardiology, and neurology because of their functionality and molecular information. This large market share of the segment is further supported by the high frequency of the diagnostic procedures and the ongoing improvement in imaging technologies.
Nuclear Medicine Market, By Volume Assessment
By assessment, the diagnostic procedures segment led the nuclear medicine market in 2024. This is because the number of PET and SPECT scans performed globally to detect early disease detection, staging, and to monitor the treatment proceeds, is very high, which is driving the growth of the segment. Since the prevalence of cancer and cardiovascular disorders is increasing, the access to nuclear imaging services is also increasing, which, in turn, is increasing the volume of procedures. Moreover, well-established diagnostic radiotracers available to facilitate repeat and consistent use are also contributing to market growth significantly.
Nuclear Medicine Market, By End User
By end user, the hospitals segment accounted for the largest share of the market in 2024. This is because hospitals have access to advanced nuclear imaging facilities, a large number of patients attending the facility and combined diagnostic and treatment services. Additionally, the availability of qualified experts and the capability to perform complex radiopharmaceutical tasks further support high adoption of nuclear medicine services in hospital settings.
REGION
Asia Pacific to be fastest-growing region in global nuclear medicine market during forecast period
Asia Pacific is projected to be the fastest-growing region in the nuclear medicine market during the forecast period. This growth is driven by the increase in cancer incidence, expansion of the hospital networks, and rising demand for diagnostic and therapeutic radiopharmaceuticals across countries such as China, India, and Japan. Market expansion is also accelerated by government initiatives to strengthen nuclear medicine infrastructure, the increasing production of radiopharmaceuticals in the country, and better regulatory frameworks. Moreover, the rising healthcare spending and the raised awareness on early diagnosis are further boosting the adoption of this regional market.
NUCLEAR MEDICINE MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX
GE HealthCare (Star) is a key player of the nuclear medicine market due to its strong focus on radiopharmaceuticals and radioisotope-enabled solutions, supported by an extensive nuclear pharmacy network and a broad portfolio of FDA-approved diagnostic and therapeutic radiopharmaceuticals. On the other hand, Eckert & Ziegler (Emerging Leader) is gaining prominence because of its expertise in the production of radioisotopes and the development of radiopharmaceuticals to serve the rising need in diagnostic and therapeutic nuclear medicines.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- GE HealthCare (US)
- Cardinal Health (US)
- Curium (France)
- Bayer AG (Germany)
- Lantheus Holdings, Inc. (US)
- Novartis AG (Switzerland)
- Jubilant Pharmova Limited (India)
- Bracco Imaging S.P.A (Italy)
- Pharmalogic Holdings Corp. (US)
- NTP Radioisotopes SOC Ltd. (South Africa)
- Nordion Inc. (Canada)
- Siemens Healthineers AG (Germany)
- NorthStar Medical Radiosiotopes, LLC (US)
- Eckert & Ziegler (Germany)
- Isotope JSC (Russia)
- Global Medical Solutions (US)
- Telix Pharmaceuticals Limited (Australia)
- PDRadiopharma Inc. (Japan)
- ITM Isotope Technologies Munich SE (Germany)
- BWX Technologies Inc. (US)
- SHINE Technologies, LLC (US)
- Isotopia (Israel)
- Institutes of Isotopes (Hungary)
- China Isotope & Radiation Corporation (China)
- IRE Elit (Turkey)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 9.03 Billion |
| Market Forecast in 2030 (Value) | USD 21.01 Billion |
| Growth Rate | CAGR of 15.1% from 2025–2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Related Segment & Geographic Reports |
US Nuclear Medicine Market Asia Pacific Nuclear Medicine Market Europe Nuclear Medicine Market |
WHAT IS IN IT FOR YOU: NUCLEAR MEDICINE MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Mapping | Profiles of leading companies (GE HealthCare, Siemens Healthineers, Curium, Cardinal Health, Lantheus, and Bracco) involved in the nuclear medicine market, based on their products and services of radiopharmaceuticals, and imaging systems (PET/SPECT) |
|
| Market Entry & Growth Strategy |
|
|
| Regulatory & Operational Risk Analysis | Analysis of the approval routes for radio pharmacy products (FDA, EMA), nuclear safety standards, licensing, and risks in the supply of isotopes |
|
| Technology Adoption Trends | Understanding adoption of new radiotracers, theranostic, PET/MR imaging, radio pharmacy automation, and image analysis using artificial intelligence |
|
RECENT DEVELOPMENTS
- December 2024 : GE HealthCare acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd. from Sumitomo Chemical, obtaining full control of the company. The acquisition is expected to bolster the company’s offerings for radiopharmaceuticals in the SPECT and PET modalities, with the deal expected to be completed in early 2025, pending approvals.
- October 2024 : Jubilant Radio pharma partnered with Simplified Imaging Solutions to enhance operational efficiencies for nuclear medicine services in the US. This brought together their national radio pharmacy network and a diagnostic services organization to create one full-service offering.
- September 2024 : General Electric HealthCare announced that it has received approval from the US Food and Drug Administration for marketing an innovative PET myocardial perfusion imaging drug called Flyrcado, or flurpiridaz F 18 injection, for diagnosing coronary artery disease.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
41
2
EXECUTIVE SUMMARY
49
3
PREMIUM INSIGHTS
55
4
MARKET OVERVIEW
Explore booming radiopharmaceuticals market driven by innovation, pharma investment, and emerging economy growth.
58
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
INCREASING INCIDENCE AND PREVALENCE OF TARGET CONDITIONS
4.2.1.2
RAPID EXPANSION OF RADIOLIGAND & TARGETED RADIONUCLIDE THERAPY
4.2.1.3
STRATEGIC ENTRY OF LARGE PHARMA & CAPITAL INFLOWS
4.2.1.4
INITIATIVES TO REDUCE DEMAND AND SUPPLY GAP OF MO-99
4.2.2
RESTRAINTS
4.2.2.1
SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
4.2.2.2
STRUCTURAL ISOTOPE SUPPLY FRAGILITY
4.2.3
OPPORTUNITIES
4.2.3.1
DEVELOPMENT OF ALPHA-RADIOIMMUNOTHERAPY-BASED TARGETED CANCER TREATMENTS
4.2.3.2
USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS
4.2.3.3
GROWTH OPPORTUNITIES IN EMERGING ECONOMIES AND EXPANDING PET INFRASTRUCTURE
4.2.4
CHALLENGES
4.2.4.1
HIGH CAPITAL INTENSITY OF NUCLEAR MEDICINE INFRASTRUCTURE AND HOSPITAL BUDGET CUTS
4.2.4.2
WORKFORCE SHORTAGE IN NUCLEAR MEDICINE
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Navigate competitive pressures and pricing dynamics shaping the future of the nuclear medicine market.
76
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
5.1.2
BARGAINING POWER OF SUPPLIERS
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
THREAT OF NEW ENTRANTS
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024
5.5.2
INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY REGION, 2024
5.6
TRADE ANALYSIS
5.6.1
IMPORT SCENARIO FOR HS CODE 2844
5.6.2
EXPORT SCENARIO FOR HS CODE 2844
5.6.3
IMPORT SCENARIO FOR HS CODE 3002
5.6.4
EXPORT SCENARIO FOR HS CODE 3002
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT & FUNDING SCENARIO
5.10
CASE STUDY ANALYSIS
5.11
IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE MARKET
5.11.1
INTRODUCTION
5.11.2
KEY TARIFF RATES
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
IMPACT ON COUNTRY/REGION
5.11.4.1
US
5.11.4.2
EUROPE
5.11.4.3
ASIA PACIFIC
5.11.5
IMPACT ON END-USE INDUSTRIES
5.11.5.1
HOSPITALS
5.11.5.2
DIAGNOSTIC & IMAGING CENTERS
5.11.5.3
RESEARCH & ACADEMIC INSTITUTES
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
Revolutionizing nuclear medicine with AI-driven precision therapies and cutting-edge radiopharmaceutical technologies.
100
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
NEXT-GENERATION RADIOLIGAND THERAPY & THERANOSTICS
6.1.2
RADIOISOTOPE PRODUCTION TECHNOLOGIES
6.1.3
HIGH-SPECIFIC-ACTIVITY RADIOLABELING AND CHELATION CHEMISTRY
6.1.4
GMP HOT-CELL MANUFACTURING & RADIOPHARMACEUTICAL QUALITY CONTROL
6.1.5
COLD KIT & GENERATOR TECHNOLOGIES
6.1.6
DECENTRALIZED ISOTOPE PRODUCTION & ADVANCED RADIOPHARMACY SYSTEMS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
AUTOMATED RADIOTRACER SYNTHESIS & DISPENSING SYSTEMS
6.2.2
DOSIMETRY & TREATMENT PLANNING TECHNOLOGIES
6.3
ADJACENT TECHNOLOGIES
6.3.1
TARGET DISCOVERY & RADIOLIGAND DESIGN PLATFORMS
6.3.2
INTEGRATED THERANOSTIC WORKFLOWS & DATA PLATFORMS
6.3.3
AI-ENABLED QUANTITATIVE IMAGING & WORKFLOW AUTOMATION
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5
PATENT ANALYSIS
6.5.1
PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE MARKET
6.5.2
INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
6.6
FUTURE APPLICATIONS
6.6.1
PRECISION ONCOLOGY & THERANOSTICS EXPANSION
6.6.2
PERSONALIZED RADIONUCLIDE THERAPY USING DOSIMETRY-GUIDED DOSING
6.6.3
EARLY DISEASE DETECTION & RISK STRATIFICATION
6.6.4
NEURODEGENERATIVE & NEUROINFLAMMATORY DISORDERS
6.6.5
INFLAMMATION, INFECTION, AND IMMUNE SYSTEM IMAGING
6.7
IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE MARKET
6.7.1
INTRODUCTION
6.7.2
MARKET POTENTIAL OF AI/GEN AI IN NUCLEAR MEDICINE MARKET
6.7.3
CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
6.7.3.1
CLINICAL VALIDATION OF AI-ENABLED STANDARDIZATION AND WORKFLOW EFFICIENCY IN PSMA PET IMAGING FOR PROSTATE CANCER
6.7.4
IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
6.7.4.1
RADIOPHARMACY, MANUFACTURING, AND QUALITY OPERATIONS
6.7.4.2
CLINICAL IMAGING, DOSIMETRY, AND TREATMENT PLANNING INFRASTRUCTURE
6.7.4.3
HOSPITAL SYSTEMS, REGULATORY COMPLIANCE, AND THERANOSTIC DATA PLATFORMS
6.7.5
USER READINESS AND IMPACT ASSESSMENT
6.7.5.1
USER READINESS
6.7.5.1.1
USER A: HOSPITALS
6.7.5.1.2
USER B: DIAGNOSTIC & IMAGING CENTERS
6.7.5.2
IMPACT ASSESSMENT
6.7.5.2.1
USER A: HOSPITALS
6.7.5.2.2
USER B: DIAGNOSTIC & IMAGING CENTERS
7
REGULATORY LANDSCAPE
Navigate complex global regulations with insights on regional compliance and key regulatory bodies.
119
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
REGULATORY FRAMEWORK
7.1.2.1
NORTH AMERICA
7.1.2.2
EUROPE
7.1.2.3
ASIA PACIFIC
7.1.2.4
LATIN AMERICA
7.1.2.5
MIDDLE EAST & AFRICA
7.1.3
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Navigate complex buyer dynamics to uncover unmet needs and enhance market profitability.
138
8.1
INTRODUCTION
8.2
DECISION-MAKING PROCESS
8.3
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3.2
BUYING CRITERIA
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5.1
UNMET NEEDS
8.5.2
END-USER EXPECTATIONS
8.6
MARKET PROFITABILITY
9
NUCLEAR MEDICINE MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 34 Data Tables
146
9.1
INTRODUCTION
9.2
DIAGNOSTIC NUCLEAR MEDICINE
9.2.1
SPECT RADIOPHARMACEUTICALS
9.2.1.1
TC-99M
9.2.1.1.1
DOMINANT ROLE OF TC-99M IN SPECT TO BOOST MARKET GROWTH
9.2.1.2
I-123
9.2.1.2.1
REDUCED EXPOSURE TO RADIATION AND LOWER RISK OF PATIENTS DEVELOPING RADIATION-INDUCED CANCER TO DRIVE DEMAND
9.2.1.3
TL-201
9.2.1.3.1
MOST COMMONLY USED SUBSTITUTE FOR TC-99M IN CARDIAC STRESS TESTS TO SUPPORT MARKET GROWTH
9.2.1.4
GA-67
9.2.1.4.1
LONG HALF-LIFE OF GA-67 TO FACILITATE EASY SALES AND DISTRIBUTION
9.2.1.5
OTHER SPECT RADIOPHARMACEUTICALS
9.2.2
PET RADIOPHARMACEUTICALS
9.2.2.1
F-18
9.2.2.1.1
ADVANTAGES SUCH AS HIGHLY ACCURATE, METABOLISM-BASED CANCER IMAGING TO BOOST DEMAND
9.2.2.2
RB-82
9.2.2.2.1
HIGH ACCURACY OFFERED BY RB-82 ISOTOPES TO SUPPORT MARKET GROWTH
9.2.2.3
OTHER PET RADIOPHARMACEUTICALS
9.3
THERAPEUTIC NUCLEAR MEDICINE
9.3.1
ALPHA EMITTERS
9.3.1.1
RA-223
9.3.1.1.1
RISING METASTATIC PROSTATE CANCER BURDEN AND DEMAND FOR BONE-TARGETED, OUTPATIENT ALPHA THERAPY TO DRIVE ADOPTION
9.3.2
BETA EMITTERS
9.3.2.1
I-131
9.3.2.1.1
I-131 TO ACCOUNT FOR LARGEST SHARE OF BETA EMITTERS MARKET DURING FORECAST PERIOD
9.3.2.2
Y-90
9.3.2.2.1
RISING INCIDENCE OF LIVER CANCERS AND HEPATOCELLULAR CARCINOMA TO PROPEL GROWTH
9.3.2.3
SM-153
9.3.2.3.1
INCREASING INCIDENCE OF BONE METASTASIS TO DRIVE MARKET
9.3.2.4
LU-177
9.3.2.4.1
RISING CANCER BURDEN AND EXPANDING PRRT ADOPTION TO FUEL GROWTH
9.3.2.5
OTHER BETA EMITTERS
9.3.3
BRACHYTHERAPY ISOTOPES
9.3.3.1
I-125
9.3.3.1.1
I-125 TO ACCOUNT FOR LARGEST SHARE OF BRACHYTHERAPY ISOTOPES MARKET
9.3.3.2
IR-192
9.3.3.2.1
PRECISE, HIGH-DOSE BRACHYTHERAPY ACROSS MULTIPLE CANCERS TO PROPEL MARKET
9.3.3.3
PD-103
9.3.3.3.1
ABILITY TO MAKE BRACHYTHERAPY PERMANENT IMPLANT SEEDS FOR EARLY-STAGE PROSTATE CANCER TO DRIVE ADOPTION
9.3.3.4
CS-131
9.3.3.4.1
GROWING USE OF CS-131 IN GYNECOLOGICAL APPLICATIONS TO AID GROWTH
9.3.3.5
OTHER BRACHYTHERAPY ISOTOPES
10
NUCLEAR MEDICINE MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 23 Data Tables
174
10.1
INTRODUCTION
10.2
DIAGNOSTIC APPLICATIONS
10.2.1
SPECT APPLICATIONS
10.2.1.1
CARDIOLOGY
10.2.1.1.1
RISING GLOBAL CARDIOVASCULAR DISEASE BURDEN AND EXPANDING, EVIDENCE-BACKED CARDIOLOGY APPLICATIONS TO DRIVE GROWTH
10.2.1.2
BONE SCANS
10.2.1.2.1
HIGH PRECISION OF SPECT TO BOOST ADOPTION OF BONE SCANS
10.2.1.3
THYROID
10.2.1.3.1
RISING DEMAND FOR COMBINATION SPECT/CT THERAPY TO DRIVE MARKET GROWTH
10.2.1.4
PULMONARY SCANS
10.2.1.4.1
HIGH ACCURACY AND SENSITIVITY OF SPECT/CT PULMONARY IMAGING TO BOOST MARKET
10.2.1.5
OTHER SPECT APPLICATIONS
10.2.2
PET APPLICATIONS
10.2.2.1
ONCOLOGY
10.2.2.1.1
INCREASING INCIDENCE OF CANCER TO FUEL MARKET GROWTH
10.2.2.2
CARDIOLOGY
10.2.2.2.1
GROWING PREFERENCE FOR FDG IN CARDIAC IMAGING TO PROPEL MARKET
10.2.2.3
NEUROLOGY
10.2.2.3.1
INCREASING INCIDENCE OF AD, EPILEPSY, AND PARKINSON’S DISEASE TO INCREASE ADOPTION OF PET IMAGING
10.2.2.4
OTHER PET APPLICATIONS
10.3
THERAPEUTIC APPLICATIONS
10.3.1
THYROID INDICATIONS
10.3.1.1
INCREASING PREVALENCE OF THYROID DISORDERS TO BOOST MARKET
10.3.2
BONE METASTASIS
10.3.2.1
INTRODUCTION OF NOVEL THERAPIES FOR BONE METASTASIS TO POSITIVELY IMPACT MARKET GROWTH
10.3.3
ENDOCRINE TUMORS
10.3.3.1
US TO DOMINATE THERAPEUTIC NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS
10.3.4
LYMPHOMA
10.3.4.1
DEVELOPMENT OF NEW ISOTOPES FOR TREATMENT OF LYMPHOMA TO PRESENT HUGE GROWTH OPPORTUNITIES
10.3.5
OTHER THERAPEUTIC APPLICATIONS
11
NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT
195
11.1
INTRODUCTION
11.2
DIAGNOSTIC PROCEDURES
11.2.1
HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH
11.3
THERAPEUTIC PROCEDURES
11.3.1
GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH
12
NUCLEAR MEDICINE MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
200
12.1
INTRODUCTION
12.2
HOSPITALS
12.2.1
GROWING VOLUME OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET GROWTH
12.3
DIAGNOSTIC & IMAGING CENTERS
12.3.1
GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
12.4
ACADEMIC & RESEARCH INSTITUTES
12.4.1
INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH
12.5
OTHER END USERS
13
NUCLEAR MEDICINE MARKET, BY REGION
Comprehensive coverage of 9 Regions with country-level deep-dive of 14 Countries | 328 Data Tables.
207
13.1
INTRODUCTION
13.2
NORTH AMERICA
13.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2
US
13.2.2.1
US TO DOMINATE NORTH AMERICAN NUCLEAR MEDICINE MARKET DURING FORECAST PERIOD
13.2.3
CANADA
13.2.3.1
INCREASING INITIATIVES FOR MEDICAL ISOTOPE DEVELOPMENT TO SUPPORT MARKET GROWTH
13.3
EUROPE
13.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2
GERMANY
13.3.2.1
WELL-ESTABLISHED HEALTHCARE SYSTEM TO DRIVE MARKET GROWTH
13.3.3
FRANCE
13.3.3.1
RISING INCIDENCE OF DISEASES SUCH AS CANCER, ALZHEIMER’S, AND PARKINSON’S DISEASE TO FAVOR MARKET GROWTH
13.3.4
UK
13.3.4.1
GROWING DEMAND FOR DIAGNOSTIC IMAGING AND GROWING AWARENESS TO DRIVE MARKET GROWTH
13.3.5
ITALY
13.3.5.1
AGING DEMOGRAPHICS, HIGH PROCEDURE VOLUMES, INCREASING CANCER INCIDENCE, AND DOMESTIC ISOTOPE SELF-SUFFICIENCY TO FUEL GROWTH
13.3.6
SPAIN
13.3.6.1
RISING DISEASE PREVALENCE, REGULATORY MODERNIZATION, AND TARGETED RADIOLIGAND EXPANSION TO CREATE SUPPORTIVE ENVIRONMENT
13.3.7
REST OF EUROPE
13.4
ASIA PACIFIC
13.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2
JAPAN
13.4.2.1
JAPAN TO DOMINATE APAC NUCLEAR MEDICINE MARKET
13.4.3
CHINA
13.4.3.1
INCREASING NUCLEAR MEDICINE INFRASTRUCTURE AND GROWING PREVALENCE OF CHRONIC DISEASES TO AUGMENT MARKET
13.4.4
INDIA
13.4.4.1
RISING CANCER AND CARDIOVASCULAR DISEASE BURDEN AND RAPID EXPANSION OF NUCLEAR MEDICINE INFRASTRUCTURE TO BOOST MARKET
13.4.5
SOUTH KOREA
13.4.5.1
ACCELERATING PET UTILIZATION AND MATURING DOMESTIC RPT INNOVATION ECOSYSTEM TO AUGMENT MARKET
13.4.6
AUSTRALIA
13.4.6.1
RISING CANCER PREVALENCE, HIGH PET PENETRATION, AND GROWING DOMESTIC ISOTOPE PRODUCTION TO SUPPORT GROWTH
13.4.7
REST OF ASIA PACIFIC
13.5
LATIN AMERICA
13.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2
BRAZIL
13.5.2.1
RISING CANCER INCIDENCE AND EXPANDING IMAGING INFRASTRUCTURE TO DRIVE MARKET
13.5.3
MEXICO
13.5.3.1
RISING CANCER AND CARDIOVASCULAR DISEASE BURDEN AND EXPANDING PRIVATE-SECTOR PET ACCESS TO DRIVE MARKET
13.5.4
REST OF LATIN AMERICA
13.6
MIDDLE EAST & AFRICA
13.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13.6.2
GCC COUNTRIES
13.6.2.1
GROWING HEALTHCARE NEEDS AND FAVORABLE GOVERNMENT SUPPORT TO BOOST MARKET
13.6.3
REST OF MIDDLE EAST & AFRICA
14
COMPETITIVE LANDSCAPE
Uncover strategic moves and market dominance of key players in nuclear medicine.
387
14.1
OVERVIEW
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET
14.3
REVENUE ANALYSIS, 2020–2024
14.4
MARKET SHARE ANALYSIS, 2024
14.5
BRAND/PRODUCT COMPARISON
14.6
COMPANY VALUATION & FINANCIAL METRICS
14.6.1
FINANCIAL METRICS
14.6.2
COMPANY VALUATION
14.7
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.7.1
STARS
14.7.2
EMERGING LEADERS
14.7.3
PERVASIVE PLAYERS
14.7.4
PARTICIPANTS
14.7.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.7.5.1
COMPANY FOOTPRINT
14.7.5.2
REGION FOOTPRINT
14.7.5.3
TYPE FOOTPRINT
14.7.5.4
APPLICATION FOOTPRINT
14.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.8.1
PROGRESSIVE COMPANIES
14.8.2
RESPONSIVE COMPANIES
14.8.3
DYNAMIC COMPANIES
14.8.4
STARTING BLOCKS
14.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
14.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.8.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
14.9
COMPETITIVE SCENARIO
14.9.1
PRODUCT APPROVALS
14.9.2
DEALS
14.9.3
EXPANSIONS
14.9.4
OTHER DEVELOPMENTS
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
414
15.1
KEY PLAYERS
15.1.1
NOVARTIS AG
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS OFFERED
15.1.1.3
RECENT DEVELOPMENTS
15.1.1.3.1
PRODUCT APPROVALS
15.1.1.3.2
DEALS
15.1.1.3.3
EXPANSIONS
15.1.1.4
MNM VIEW
15.1.1.4.1
RIGHT TO WIN
15.1.1.4.2
STRATEGIC CHOICES
15.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
15.1.2
LANTHEUS HOLDINGS, INC.
15.1.3
GE HEALTHCARE
15.1.4
CURIUM
15.1.5
TELIX PHARMACEUTICALS LIMITED
15.1.6
SIEMENS HEALTHINEERS
15.1.7
CHINA ISOTOPE & RADIATION CORPORATION
15.1.8
BAYER AG
15.1.9
BRACCO IMAGING S.P.A.
15.1.10
CARDINAL HEALTH
15.1.11
JUBILANT PHARMOVA LIMITED
15.1.12
ELI LILLY AND COMPANY
15.1.13
BWXT MEDICAL LTD.
15.1.14
NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
15.1.15
ECKERT & ZIEGLER
15.1.16
ISOTOPE JSC
15.1.17
PDRADIOPHARMA INC.
15.1.18
ITM ISOTOPE TECHNOLOGIES MUNICH SE
15.1.19
NARODOWE CENTRUM BADAN JADROWYCH OSRODEK RADIOIZOTOPÓW – POLATOM
15.1.20
ANSTO
15.2
OTHER PLAYERS
15.2.1
SHINE TECHNOLOGIES, LLC
15.2.2
ISOTOPIA MOLECULAR IMAGING LTD.
15.2.3
INSTITUTE OF ISOTOPES
15.2.4
GLOBAL MEDICAL SOLUTIONS
15.2.5
ISOTEX DIAGNOSTICS
16
RESEARCH METHODOLOGY
506
16.1
RESEARCH DATA
16.2
RESEARCH APPROACH
16.2.1
SECONDARY RESEARCH
16.2.1.1
KEY DATA FROM SECONDARY SOURCES
16.2.2
PRIMARY RESEARCH
16.2.2.1
PRIMARY SOURCES
16.2.2.2
KEY DATA FROM PRIMARY SOURCES
16.2.2.3
BREAKDOWN OF PRIMARIES
16.2.2.4
INSIGHTS FROM PRIMARY EXPERTS
16.3
RESEARCH METHODOLOGY DESIGN
16.4
MARKET SIZE ESTIMATION
16.4.1
APPROACH 1: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH – SUPPLY-SIDE ANALYSIS)
16.4.2
APPROACH 2: SECONDARY DATA & PRIMARY INTERVIEWS
16.4.3
APPROACH 3: SEGMENTAL MARKET SIZE ASSESSMENT
16.4.4
APPROACH 4: TOP-DOWN APPROACH
16.4.5
GROWTH FORECAST
16.4.6
GEOGRAPHIC MARKET ASSESSMENT (BY REGION AND COUNTRY)
16.5
MARKET BREAKDOWN & DATA TRIANGULATION
16.6
STUDY ASSUMPTIONS
16.7
RESEARCH LIMITATIONS
16.7.1
METHODOLOGY-RELATED LIMITATIONS
16.7.2
SCOPE-RELATED LIMITATIONS
16.8
RISK ASSESSMENT
17
APPENDIX
524
17.1
DISCUSSION GUIDE
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
17.4
RELATED REPORTS
17.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2
MAIN MO-99 PRODUCTION REACTORS
TABLE 3
RADIOPHARMACEUTICALS: PHYSICAL HALF-LIFE AND MAJOR CLINICAL APPLICATIONS
TABLE 4
UK: NUCLEAR MEDICINE-RELATED WORKFORCE AND VACANCY DATA, 2021
TABLE 5
NUCLEAR MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 6
NUCLEAR MEDICINE MARKET: ROLE IN ECOSYSTEM
TABLE 7
INDICATIVE PRICE OF NUCLEAR MEDICINE PRODUCTS, BY TYPE, 2024
TABLE 8
INDICATIVE PRICE OF NUCLEAR MEDICINE IN EASTERN EUROPE, BY TYPE, 2024
TABLE 9
INDICATIVE PRICE OF NUCLEAR MEDICINE IN MENAT REGION, BY TYPE, 2024
TABLE 10
AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN INDIA, BY TYPE, 2024
TABLE 11
IMPORT VALUE FOR HS CODE 2844, 2020–2024 (USD THOUSAND)
TABLE 12
EXPORT VALUE FOR HS CODE 2844, 2020–2024 (USD THOUSAND)
TABLE 13
IMPORT VALUE FOR HS CODE 3002, 2020–2024 (USD THOUSAND)
TABLE 14
EXPORT VALUE FOR HS CODE 3002, 2020–2024 (USD THOUSAND)
TABLE 15
NUCLEAR MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 16
CASE 1: BETA-AMYLOID PET/CT IMAGING ENABLES ALZHEIMER'S PATIENT QUALIFICATION FOR ANTI-AMYLOID THERAPY AT NEW YORK-PRESBYTERIAN HOSPITAL
TABLE 17
CASE 2: WHOLE-BODY PET/CT WITH EXTENDED AXIAL FOV ENABLES DETECTION OF RARE PERICARDIAL RECURRENCE IN PLEURAL MESOTHELIOMA AT RIGSHOSPITALET
TABLE 18
CASE 3: CLINICAL AND OPERATIONAL IMPACT OF IMPLEMENTING AN INTEGRATED THERANOSTICS PROGRAM IN BRAZIL
TABLE 19
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 20
JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE MARKET
TABLE 21
NUCLEAR MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS
TABLE 22
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27
REGULATORY SCENARIO OF NORTH AMERICA
TABLE 28
REGULATORY SCENARIO OF EUROPE
TABLE 29
REGULATORY SCENARIO OF ASIA PACIFIC
TABLE 30
REGULATORY SCENARIO OF LATIN AMERICA
TABLE 31
REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
TABLE 32
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
TABLE 33
KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 34
UNMET NEEDS IN NUCLEAR MEDICINE MARKET
TABLE 35
END-USER EXPECTATIONS IN NUCLEAR MEDICINE MARKET
TABLE 36
NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 37
DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 38
DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 39
ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES
TABLE 40
SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 41
SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 42
TC-99M MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 43
I-123 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 44
TI-201 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
GA-67 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 46
OTHER SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 47
PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 48
PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 49
F-18 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
RB-82 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 51
OTHER PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 52
THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 53
THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 54
ALPHA EMITTERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 55
RA-223 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 56
BETA EMITTERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 57
BETA EMITTERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 58
I-131 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 59
Y-90 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
SM-153 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 61
LU-177 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 62
OTHER BETA EMITTERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 63
BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 64
BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 65
I-125 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 66
IR-192 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
PD-103 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 68
CS-131 MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 69
OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 71
NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 72
NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 73
NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 74
NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 76
NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 77
NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 78
NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 79
NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 80
NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 81
NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 83
NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 85
NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 86
NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 87
NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 88
NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 90
NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 91
NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 92
NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 93
NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2023–2030 (THOUSAND PROCEDURES)
TABLE 94
NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (THOUSAND PROCEDURES)
TABLE 95
NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2023–2030 (THOUSAND PROCEDURES)
TABLE 96
NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2023–2030 (THOUSAND PROCEDURES)
TABLE 97
NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2023–2030 (THOUSAND PROCEDURES)
TABLE 98
NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 99
NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
TABLE 100
NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 101
NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 102
NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 103
NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 104
NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 105
NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 107
NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 108
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 109
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 110
NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 111
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 112
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 113
NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 114
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 115
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 116
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 117
NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 118
NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 119
US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 120
US: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 121
US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 122
US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 123
US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 124
US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 125
US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 126
US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 127
US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 128
US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 129
US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 130
US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 131
US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 132
US: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 133
CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 134
CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 135
CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 136
CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 137
CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 138
CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 139
CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 140
CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 141
CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 142
CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 143
CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 144
CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 145
CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 146
CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 147
EUROPE: KEY MACROECONOMIC INDICATORS
TABLE 148
EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 150
EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 151
EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 152
EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 153
EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 154
EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 155
EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 156
EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 157
EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 158
EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 159
EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 160
EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 161
EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 162
GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 163
GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 164
GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 165
GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 166
GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 167
GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 168
GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 169
GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 170
GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 171
GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 172
GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 173
GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 174
GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 175
FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 176
FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 177
FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 178
FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 179
FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 180
FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 181
FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 182
FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 183
FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 184
FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 185
FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 186
FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 187
FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 188
FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 189
UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 190
UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 191
UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 192
UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 193
UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 194
UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 195
UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 196
UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 197
UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 198
UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 199
UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 200
UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 201
UK: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 202
ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 203
ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 204
ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 205
ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 206
ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 207
ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 208
ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 209
ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 210
ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 211
ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 212
ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 213
ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 214
ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 215
ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 216
SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 217
SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 218
SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 219
SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 220
SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 221
SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 222
SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 223
SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 224
SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 225
SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 226
SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 227
SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 228
SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 229
REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 230
REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 231
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 232
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 233
REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 234
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 235
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 236
REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 237
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 238
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 239
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 240
REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 241
REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 242
ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
TABLE 243
ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244
ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245
ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 246
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 247
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 248
ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 249
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 250
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 251
ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 252
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 253
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 254
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 255
ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 256
ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 257
JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 258
JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 259
JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 260
JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 261
JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 262
JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 263
JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 264
JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 265
JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 266
JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 268
JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 269
JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 270
CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 271
CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 272
CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273
CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 274
CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 275
CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 276
CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 277
CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 278
CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 279
CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 282
CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283
CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 284
INDIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 285
INDIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 286
INDIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 287
INDIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
INDIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 289
INDIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 290
INDIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291
INDIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 292
INDIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 293
INDIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294
INDIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 295
INDIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 296
INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 297
SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 298
SOUTH KOREA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 299
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
SOUTH KOREA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 303
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 304
SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 306
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 307
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 308
SOUTH KOREA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 309
SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 310
AUSTRALIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 311
AUSTRALIA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 312
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 313
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 314
AUSTRALIA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 316
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 317
AUSTRALIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 318
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 320
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 321
AUSTRALIA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 322
AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 323
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324
REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 325
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 326
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327
REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 328
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 329
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 330
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 331
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 332
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 333
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 334
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335
REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 336
LATIN AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 337
LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 338
LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 339
LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 340
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 341
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 342
LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 344
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345
LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 346
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 347
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 348
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 349
LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 350
LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 351
BRAZIL: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 352
BRAZIL: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353
BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 354
BRAZIL: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 355
BRAZIL: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 356
BRAZIL: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 357
BRAZIL: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 358
BRAZIL: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 359
BRAZIL: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 360
BRAZIL: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361
BRAZIL: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 362
BRAZIL: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 363
BRAZIL: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 364
MEXICO: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 365
MEXICO: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 366
MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367
MEXICO: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 368
MEXICO: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 369
MEXICO: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 370
MEXICO: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 371
MEXICO: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 372
MEXICO: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 373
MEXICO: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 374
MEXICO: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 375
MEXICO: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 376
MEXICO: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 377
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 378
REST OF LATIN AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 379
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 380
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381
REST OF LATIN AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 382
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 383
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 384
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 385
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 386
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 387
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 388
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 389
REST OF LATIN AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 390
MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS
TABLE 391
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 392
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 393
MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 394
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 395
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 396
MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 397
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 398
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 399
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 400
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 401
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 402
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 403
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 404
MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 405
GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 406
GCC COUNTRIES: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 407
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 408
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 409
GCC COUNTRIES: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 410
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 411
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 412
GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 413
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 414
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 415
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 416
GCC COUNTRIES: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 417
GCC COUNTRIES: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 418
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 419
REST OF MIDDLE EAST & AFRICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 420
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 421
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 422
REST OF MIDDLE EAST & AFRICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 423
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 424
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2023–2030 (USD MILLION)
TABLE 425
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 426
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 427
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 428
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 429
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 430
REST OF MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 431
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE, JANUARY 2022–DECEMBER 2025
TABLE 432
NUCLEAR MEDICINE MARKET: DEGREE OF COMPETITION
TABLE 433
NUCLEAR MEDICINE MARKET: REGION FOOTPRINT
TABLE 434
NUCLEAR MEDICINE MARKET: TYPE FOOTPRINT
TABLE 435
NUCLEAR MEDICINE MARKET: APPLICATION FOOTPRINT
TABLE 436
NUCLEAR MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
TABLE 437
NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
TABLE 438
NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY TYPE
TABLE 439
NUCLEAR MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY APPLICATION
TABLE 440
NUCLEAR MEDICINE MARKET: PRODUCT APPROVALS, JANUARY 2022– DECEMBER 2025
TABLE 441
NUCLEAR MEDICINE MARKET: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 442
NUCLEAR MEDICINE MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 443
NUCLEAR MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 444
NOVARTIS AG: COMPANY OVERVIEW
TABLE 445
NOVARTIS AG: PRODUCTS OFFERED
TABLE 446
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 447
NOVARTIS AG: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 448
NOVARTIS AG: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 449
LANTHEUS HOLDINGS, INC.: COMPANY OVERVIEW
TABLE 450
LANTHEUS HOLDINGS, INC.: PRODUCTS OFFERED
TABLE 451
LANTHEUS HOLDINGS, INC.: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 452
GE HEALTHCARE: COMPANY OVERVIEW
TABLE 453
GE HEALTHCARE: PRODUCTS OFFERED
TABLE 454
GE HEALTHCARE: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 455
GE HEALTHCARE: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 456
GE HEALTHCARE: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 457
GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 458
CURIUM: COMPANY OVERVIEW
TABLE 459
CURIUM: PRODUCTS OFFERED
TABLE 460
CURIUM: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2022–DECEMBER 2025
TABLE 461
CURIUM: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 462
CURIUM: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 463
CURIUM: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 464
TELIX PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
TABLE 465
TELIX PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
TABLE 466
TELIX PHARMACEUTICALS LIMITED: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 467
TELIX PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 468
TELIX PHARMACEUTICALS LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 469
SIEMENS HEALTHINEERS: COMPANY OVERVIEW
TABLE 470
SIEMENS HEALTHINEERS: PRODUCTS OFFERED
TABLE 471
SIEMENS HEALTHINEERS: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 472
SIEMENS HEALTHINEERS: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 473
CHINA ISOTOPE & RADIATION CORPORATION: COMPANY OVERVIEW
TABLE 474
CHINA ISOTOPE & RADIATION CORPORATION: PRODUCTS OFFERED
TABLE 475
CHINA ISOTOPE & RADIATION CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 476
BAYER AG: COMPANY OVERVIEW
TABLE 477
BAYER AG: PRODUCTS OFFERED
TABLE 478
BAYER AG: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 479
BRACCO IMAGING S.P.A.: COMPANY OVERVIEW
TABLE 480
BRACCO IMAGING S.P.A.: PRODUCTS OFFERED
TABLE 481
BRACCO IMAGING S.P.A.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 482
BRACCO IMAGING S.P.A.: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 483
BRACCO IMAGING S.P.A.: OTHER DEVELEOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 484
CARDINAL HEALTH: COMPANY OVERVIEW
TABLE 485
CARDINAL HEALTH: PRODUCTS OFFERED
TABLE 486
CARDINAL HEALTH: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 487
JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW
TABLE 488
JUBILANT PHARMOVA LIMITED: PRODUCTS OFFERED
TABLE 489
JUBILANT PHARMOVA LIMITED: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 490
JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 491
JUBILANT PHARMOVA LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 492
ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 493
ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 494
ELI LILLY AND COMPANY: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 495
ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 496
BWXT MEDICAL LTD.: COMPANY OVERVIEW
TABLE 497
BWXT MEDICAL LTD.: PRODUCTS OFFERED
TABLE 498
BWXT MEDICAL LTD.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 499
NTP RADIOISOTOPES SOC LTD.: COMPANY OVERVIEW
TABLE 500
NTP RADIOISOTOPES SOC LTD.: PRODUCTS OFFERED
TABLE 501
NTP RADIOISOTOPES SOC LTD.: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 502
ECKERT & ZIEGLER: COMPANY OVERVIEW
TABLE 503
ECKERT & ZIEGLER: PRODUCTS OFFERED
TABLE 504
ECKERT & ZIEGLER: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 505
ECKERT & ZIEGLER: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 506
ECKERT & ZIEGLER: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 507
JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): COMPANY OVERVIEW
TABLE 508
ISOTOPE JSC: PRODUCTS OFFERED
TABLE 509
ISOTOPE JSC: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 510
ISOTOPE JSC: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 511
PDRADIOPHARMA INC.: COMPANY OVERVIEW
TABLE 512
PDRADIOPHARMA INC.: PRODUCTS OFFERED
TABLE 513
PDRADIOPHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 514
PDRADIOPHARMA INC.: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 515
PDRADIOPHARMA INC.: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 516
ITM ISOTOPE TECHNOLOGIES MUNICH SE: COMPANY OVERVIEW
TABLE 517
ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCTS OFFERED
TABLE 518
ITM ISOTOPE TECHNOLOGIES MUNICH SE: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025
TABLE 519
ITM ISOTOPE TECHNOLOGIES MUNICH SE: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 520
ITM ISOTOPE TECHNOLOGIES MUNICH SE: EXPANSIONS, JANUARY 2022–DECEMBER 2025
TABLE 521
ITM ISOTOPE TECHNOLOGIES MUNICH SE: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 522
NARODOWE CENTRUM BADAN JADROWYCH OSRODEK RADIOIZOTOPÓW – POLATOM: COMPANY OVERVIEW
TABLE 523
NARODOWE CENTRUM BADAN JADROWYCH OSRODEK RADIOIZOTOPÓW – POLATOM: PRODUCTS OFFERED
TABLE 524
NARODOWE CENTRUM BADAN JADROWYCH OSRODEK RADIOIZOTOPÓW – POLATOM: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 525
ANSTO: COMPANY OVERVIEW
TABLE 526
ANSTO: PRODUCTS OFFERED
TABLE 527
ANSTO: DEALS, JANUARY 2022–DECEMBER 2025
TABLE 528
ANSTO: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025
TABLE 529
RISK ASSESSMENT: NUCLEAR MEDICINE MARKET
LIST OF FIGURES
FIGURE 1
NUCLEAR MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
MARKET SCENARIO
FIGURE 3
GLOBAL NUCLEAR MEDICINE MARKET, 2023–2030
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2022–2025
FIGURE 5
DISRUPTIONS INFLUENCING GROWTH OF NUCLEAR MEDICINE MARKET
FIGURE 6
HIGH-GROWTH SEGMENTS IN NUCLEAR MEDICINE MARKET, 2025–2030
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NUCLEAR MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8
RAPID EXPANSION OF RADIOLIGAND AND TARGETED RADIONUCLIDE THERAPY TO DRIVE MARKET GROWTH
FIGURE 9
DIAGNOSTIC NUCLEAR MEDICINE MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024
FIGURE 10
INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 11
GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD
FIGURE 12
NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13
ESTIMATED NUMBER OF NEW CASES IN EMERGING ECONOMIES, 2022–2050
FIGURE 14
NUCLEAR MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15
GLOBAL GDP GROWTH, 2020–2030
FIGURE 16
NUCLEAR MEDICINE MARKET: VALUE CHAIN ANALYSIS (2024)
FIGURE 17
NUCLEAR MEDICINE MARKET: ECOSYSTEM ANALYSIS
FIGURE 18
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20
PATENT APPLICATION TRENDS IN NUCLEAR MEDICINE MARKET, 2015–2026
FIGURE 21
JURISDICTION & TOP APPLICANT ANALYSIS FOR NUCLEAR MEDICINE MARKET
FIGURE 22
TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE MARKET (JANUARY 2015–FEBRUARY 2026)
FIGURE 23
MARKET POTENTIAL OF AI/GEN AI ON NUCLEAR MEDICINE ACROSS END USERS
FIGURE 24
IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
FIGURE 25
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
FIGURE 26
KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 27
NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
FIGURE 28
ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2024)
FIGURE 29
REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2020–2024
FIGURE 30
MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE MARKET, 2024
FIGURE 31
NUCLEAR MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 32
EV/EBITDA OF KEY VENDORS
FIGURE 33
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 34
NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 35
NUCLEAR MEDICINE MARKET: COMPANY FOOTPRINT
FIGURE 36
NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 37
NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 38
LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2024)
FIGURE 39
GE HEALTHCARE: COMPANY SNAPSHOT (2024)
FIGURE 40
TELIX PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 41
SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2024)
FIGURE 42
CHINA ISOTOPE & RADIATION CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 43
BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 44
CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
FIGURE 45
JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 46
ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
FIGURE 47
ECKERT & ZIEGLER: COMPANY SNAPSHOT (2024)
FIGURE 48
ANSTO: COMPANY SNAPSHOT (2024)
FIGURE 49
RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
FIGURE 50
RESEARCH DESIGN
FIGURE 51
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 52
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 53
SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 54
NUCLEAR MEDICINE MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 55
NUCLEAR MEDICINE MARKET: REVENUE ANALYSIS OF TOP FOUR COMPANIES (2024)
FIGURE 56
NUCLEAR MEDICINE MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 57
NUCLEAR MEDICINE MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 58
CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN NUCLEAR MEDICINE INDUSTRY
FIGURE 59
CAGR PROJECTIONS: NUCLEAR MEDICINE MARKET, 2025−2030
FIGURE 60
DATA TRIANGULATION METHODOLOGY
Methodology
This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.
Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
Breakdown of Primary Interviews
Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
Report Metric |
Details |
|
Siemens Healthineers |
Sr.Sales Manager |
|
Curium |
General Manager |
|
Cardinal Health |
Product Sales Specialist |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.
Market Definition
Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.
Key Stakeholders
- Senior Management
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
- To profile the key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market
Available Customizations
MarketsandMarkets offers the following customizations for this market report:
- Additional country-level analysis of the nuclear medicine market.
- Profiling of additional market players (up to 3)
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationGrowth opportunities and latent adjacency in Nuclear Medicine Market
Still Researching the
Nuclear Medicine Ecosystem?
See the competitors, opportunity evaluation, and growth signals shaping it - Instantly!
Generate 15+ consulting-grade strategic intelligence outputs - from competitor analysis to board-ready strategy decks, tailored to your Nuclear Medicine growth question.
John
May, 2022
Which segment accounted for the largest nuclear medicine market share?.
Kahlill
May, 2022
Which region has highest growth rate in Nuclear Medicine Market / Radiopharmaceuticals Market ?.
Rachel
May, 2022
Keen to get the updates on Nuclear Medicine Market Size Report, 2022 - 2030 .